会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Anti-CD19 antibodies and uses in oncology
    • 抗CD19抗体及其在肿瘤学中的应用
    • US20060233791A1
    • 2006-10-19
    • US11355905
    • 2006-02-15
    • Thomas TedderYasuhito HamaguchiHanne GronNorihito Yazawa
    • Thomas TedderYasuhito HamaguchiHanne GronNorihito Yazawa
    • A61K39/395
    • C07K16/2803A61K2039/505A61K2039/54C07K2317/56C07K2317/565C07K2317/567C07K2317/77
    • The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    • 本发明涉及使用结合人CD19抗原并优选介导人ADCC的治疗性抗体来治疗人受试者中B细胞疾病和障碍的免疫治疗组合物和方法,所述B细胞疾病和病症例如但不限于B细胞恶性肿瘤。 本发明涉及包含IgG1或IgG3人同种型的人或人源化抗CD19抗体的药物组合物。 本发明涉及药物组合物,其包含优选介导人ADCC的IgG2或IgG4人同种型人或人源化抗CD19抗体。 本发明还涉及包含介导人ADCC的IgG1,IgG2,IgG3或IgG4同种型的嵌合抗CD19抗体的药物组合物。 在优选的实施方案中,本发明涉及包含单克隆人,人源化或嵌合抗-CD19抗体的药物组合物。
    • 7. 发明申请
    • ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY
    • 抗CD19抗体及其在肿瘤学中的应用
    • US20090285808A1
    • 2009-11-19
    • US12401310
    • 2009-03-10
    • Thomas F. TedderYasuhito HamaguchiHanne GronNorihito Yazawa
    • Thomas F. TedderYasuhito HamaguchiHanne GronNorihito Yazawa
    • A61K39/395
    • C07K16/2803A61K2039/505A61K2039/54C07K2317/56C07K2317/565C07K2317/567C07K2317/77
    • The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    • 本发明涉及使用结合人CD19抗原并优选介导人ADCC的治疗性抗体来治疗人受试者中B细胞疾病和障碍的免疫治疗组合物和方法,所述B细胞疾病和病症例如但不限于B细胞恶性肿瘤。 本发明涉及包含IgG1或IgG3人同种型的人或人源化抗CD19抗体的药物组合物。 本发明涉及药物组合物,其包含优选介导人ADCC的IgG2或IgG4人同种型人或人源化抗CD19抗体。 本发明还涉及包含介导人ADCC的IgG1,IgG2,IgG3或IgG4同种型的嵌合抗CD19抗体的药物组合物。 在优选的实施方案中,本发明涉及包含单克隆人,人源化或嵌合抗-CD19抗体的药物组合物。